Karolinska Development's portfolio company Modus Theraputics has secured two new US-based patents for its drug sevuparin.

The two patents have been granted claims for the substance sevuparin per se and a manufacturing method for producing sevuparin, as well as its use in sickle-cell disease (SCD).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The patents granted by the United States Patent and Trademark Office (USPTO) will enable key intellectual property protection in the US for sevuparin until at least December 2032.

Modus Therapeutics is currently enrolling SCD patients into a multi-centre, international, randomised Phase II study in Europe and the Middle East.

"The grant of these two US patents is a major milestone for Modus Therapeutics as they provide important IP protection for sevuparin and its use for SCD."

This proof-of-concept study is intended to show reduced time to resolution of Vaso-Occlusive Crises (VOC) in SCD patients.

Modus Therapeutics CEO Christina Herder said: “The grant of these two US patents is a major milestone for Modus Therapeutics as they provide important IP protection for sevuparin and its use for SCD.

"The US has an estimated 100,000 SCD patients, and therefore represents a significant opportunity for sevuparin.”

Karolinska Development chief investment officer Viktor Drvota said: “This is a positive development for Modus Therapeutics, providing a strong foundation for the development and future commercialisation of sevuparin in the US.”